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Abstract PC12 pheochromocytoma cells possess four known 
MEK activators: A-, B-, c-Raf-I and MEKK. In order to 
examine whether differentiation factors or growth factors have a 
Raf isozyme preference for activation of the mitogenic ytoplas- 
mic Raf-MEK-MAPK protein kinase cascade, the activation 
kinetics of these enzymes in response to epidermal growth factor 
(EGF) and nerve growth factor (NGF) were compared. An initial 
activation of all three Raf kinases was noticed, but only A- and 
B-Raf showed sustained activation by NGF, which was not seen 
after EGF treatment. Furthermore, expression of oncogenic 
versions of all three Raf kinases as weil~ as a potentially Raf- 
independent MEK activator, v-Mos, leads to activation of 
MAPK and to differentiation of PC12 cells. These data suggest 
a differential regulation of Raf kinases and that probably no 
alternative Raf substrates are involved in differentiation 
processes of PC12 cells. 
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1. Introduction 
sent in brain tissue [10]. It was therefore reasonable to expect 
that there may be functional differences between A-, B- and 
c-Raf-ls, although at least under conditions of overexpression 
they clearly overlapped in the ability to recruit the classic 
cytoplasmic cascade [11]. In fact, recent work on cAMP sen- 
sitivity of B-Raf versus c-Raf-1 in PC12 pheochromocytoma 
cells demonstrated differential regulation [12] and the use of 
chimeric oestrogen receptor Raf fusion proteins in NIH 3T3 
and Ratla fibroblast cell lines indicated differences in the 
specific activities towards the common substrate MEK and 
suggested ifferences in substrate choice [13]. One cell system 
in which all three Raf isozymes are expressed and which can 
be induced by growth factors to either differentiate or prolif- 
erate are PC12 pheochromocytoma cells [2,14,15]. In order to 
examine whether differentiation versus growth factor recep- 
tors would have an isozyme preference for activation of the 
classic cascade, we decided to determine the kinetics of activa- 
tion of all three Raf isozymes by nerve growth factor (NGF) 
and epidermal growth factor (EGF), the effect of their onco- 
genic versions on activation of MAP kinase and on differen- 
tiation. 
The function of Raf serine/threonine protein kinases is com- 
monly associated with transmission of proliferation signals 
following growth factor receptor stimulation in mammalian 
cells. Signal transmission i volves recruitment of a highly con- 
served protein kinase cascade consisting of the dual-specificity 
mitogen-activated protein kinase kinase (MEK) and its sub- 
strate, a serine/threonine specific mitogen-activated protein 
kinase (MAPK). Early work with an oncogenic version of 
Raf-1 (v-Raf) that was transduced as part of a retrovirus, 
3611 MSV [1], demonstrated that constitutive xpression of 
Raf-1 kinase also influenced differentiation processes (re- 
viewed by Rapp et al. [2]). Specifically, upon infection of new- 
born mice an altered fate was observed in erythroid, B/mye- 
loid and epithelial lineages [3] and upon infection of 
progenitor cells in culture erythroid, adipocyte or neuronal 
differentiation was induced [4-7]. When v-Raf was combined 
with another growth factor inducible cell cycle-progression 
regulator, v-myc, induction of differentiation f early progeni- 
tors of the B-lineage to mature lymphocytes was observed that 
was associated with a tendency to switch to the myeloid line- 
age [5,8]. When comparison was made with the activity of 
oncogenic forms of other Raf isozymes, A- and B-Raf, there 
was a suggestion of tissue specific transforming/differentiation 
effects [9]. The three Raf isozymes, A-, B- and c-Raf-1 differ 
in their tissue specific pattern of expression i  that c-Raf-1 is 
present in all tissues, A-Raf adds to Raf-1 expression pre- 
dominantly in urogenital tissues and B-Raf is primarily pre- 
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2. Materials and methods 
2.1. Cell culture 
PC12 cells were cultured as described by Troppmair et al. [6]. Ti- 
tration of NGF or EGF showed that maximal activation of Raf is 
achieved with 25 ng/ml of growth factors. Therefore, all treatments 
with growth factors were performed using 50 ng/ml NGF or EGF 
(Gibco BRL). All experiments were performed inmedium with serum. 
No starved cells were used. All retroviral infections were performed as 
described [6]. 
2.2. Antisera 
Rabbit polyclonal ntisera to MAPK, and MEKK were from Santa 
Cruz Biotechnology. Antibodies against c-Raf-1 and B-Raf were di- 
rected to the isozyme specific C-terminal 13 amino acids. Anti A-Raf 
serum was generated with a 30 kDa peptide of the kinase domain. No 
cross reaction of the antibodies with the different Raf isozymes was 
observed in immonoprecipitation or immunoblotting [16,17]. 
2.3. Expression and purification of recombinant substrates 
GST-MEK and the mutant enzyme K97M MEK were purified as 
described [18,19] except that for K97M MEK an additional Mono Q 
purification step was performed and that the eluate was dialysed 
against buffer containing 25 mM HEPES, pH 7.5, 25 mM Na-glycer- 
ophosphate, 1.5 mM EGTA, 5% glycerol and 1 mM DTT. The bac- 
terially expressed ERK2His6 (K52R) protein was purified as described 
[20]. 
2.4. Immunoprecipitations and kinase assays 
PC12 cells were rinsed twice with phosphate-buffered saline, 
scraped into chilled buffer A (50 mM Tris-HC1 pH 8.0, 137 mM 
NaC1, 1% Triton X-100, 10 mM Na-pyrophosphate, 25 mM Na-gly- 
cerophosphate, 2 mM EDTA, 2 mM EGTA, 10% glycerol, 0.1% 2- 
mercaptoethanol, 1 mM Na-vanadate, 25 mM NaF, 0.01% leupeptin, 
0.01% aprotinin, 2 mM pepstatin) and centrifuged at 1000Xg for 
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5 min at 4°C. 400/ag of protein per sample were rotated at 4°C for 2 h 
with 25 lal protein A agarose beads and anti-Raf sera. The immune 
complexes were washed twice with buffer A and once with buffer B 
(25 mM HEPES pH 7.5, 25 mM Na-glycerophosphate, 1.5 mM 
EGTA, 5% glycerol, 1 mM DTT) and pellets were resuspended in 
30 ~tl buffer B supplemented with 10 mM MgCI2, 100 ~M ATP, 10 
laCi [7-32P]ATP (3000 Ci/mM, Amersham) and with 4 ~tg K97M MEK 
and incubated at 30°C for 15 min. Reactions were stopped by the 
addition of 4 × Laemmli sample buffer. Proteins were separated by 
SDS-polyacrylamide gelelectrophoresis (PAGE) and transferred to 
nitrocellulose membrane. Quantification of the amount of substrate 
phosphorylation was performed by a BAS 2000 II Fuji phosphoima- 
ger. The quality of immunoprecipitations wa  checked by immunoblot 
analysis using horseradish peroxidase-conjugated secondary antibod- 
ies and the ECL detection system (Amersham). To minimise xperi- 
mental variability, the enzymatic activity of all Raf kinases as well as 
MEK and MAPK was quantified simultaneously in the same PC12 
cell extract. The kinase activation values of stimulated cells were nor- 
malised to unstimulated cells, the activity of which was taken as unity. 
For the coupled Raf-MEK-MAPK kinase assay the Raf immune 
complexes were incubated for 10 min at 30°C as described above 
but without radiolabeled ATP and with 2.0 ~tg GST-MEK. After- 
wards 2.5 ~tg of the kinase inactive mutant of ERK2 and 10 p.Ci [7- 
32p]ATP was added and the mixture was incubated for additional 15 
min at 30°C. The kinase activity of MEK and MAPK enzymes was 
estimated in the same manner as Raf kinases. As substrates 2.5 ~tg of 
ERK2His6 and 2.5 /.tg of myelin basic protein (MBP, UBI), respec- 
tively, were used. 
3. Results 
3.1. NGF induces sustained activation of A-Raf and B-Raf in 
PC12 cells 
The enzymatic activation of all three Raf kinases as well as 
MEKK after addition of NGF or EGF to PC12 cell culture is 
presented in Fig. 1. The levels of Raf proteins did not change 
during the time course of stimulation as judged from immu- 
noblot experiments (data not shown). Both growth factors 
induced rapid activation of c-Raf-1 with a maximum after 
1 2.5 min of stimulation. No difference between differentia- 
tion (NGF) and proliferation (EGF) inducing signals was no- 
ticed. The 4-5-fold activation of c-Raf-1 declined after 30 min 
of growth factor stimulation to only 1.5-fold basal level and 
was indistinguishable from unstimulated cells after 3 h 
(Fig. 1A). 
The activation kinetics of B- and A-Raf (Fig. I C,D) were 
different from those of c-Raf-1. Initial induction was less rap- 
id and the maximally achieved stimulation was not higher 
than 3-fold. Besides differences in levels, the pattern of activa- 
tion differed remarkably between the Raf isozymes. Stimula- 
tion of A- and B-Raf kinase activity was biphasic with an 
early peak after 5 min being followed by a second peak after 
60-90 rain. Biphasic kinetics were noted for exposure to both 
NGF and EGF, but were more pronounced, especially in the 
case of A-Raf, after NGF stimulation. It is interesting that 
similar kinetics with peaks after 5 and 60 rain were described 
in [21] for p21 Ras activation after NGF stimulation of PC12 
cells and it was expected that the activity of B-Raf would 
follow most closely that of Ras. Surprisingly, it was the stim- 
ulation of A-Raf that best paralleled Ras activation (Fig. 1D 
and [21]). As Raf kinases are not the only MEK activators in 
PC12 cells, we also examined other enzymes. Both NGF and 
EGF induced biphasic activation of MEKK, however, in this 
case there was no significant difference in the level of induc- 
tion. If anything, levels after EGF treatment were higher than 
after NGF treatment (Fig. 1B). These data suggest hat A- 
and B-Raf but not c-Raf-1 or MEKK are involved in differ- 
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entiation induction by NGF. In order to show that the phos- 
phorylation of MEK by Raf kinases is an activating phos- 
phorylation, we performed the coupled MEK-MAPK kinase 
assay. Immune complexes of all Raf kinases and of MEKK 
were able to induce MAPK phosphorylation after NGF or 
EGF stimulation through activation of GST-MEK (data not 
shown). 
The pattern of MEK activation differs from that of c-Raf-1, 
as the initial peak is 4-fold higher with either EGF or NGF 
and the activity remains elevated for more than 90 min after 
NGF treatment (data not shown). The differential ability of 
NGF but not EGF to induce sustained activity was also re- 
flected at the level of MEK and MAPK (data not shown and 
[21-23]). Thus, the rapid and high activation of MEK and 
subsequently of MAPK by NGF and EGF correlated with 
the rapid and high activation of c-Raf-1, and the prolonged 
activity of MEK and MAPK in response to NGF compared 
to EGF correlated with a sustained activity of A-Raf and B- 
Raf. 
3.2. Effect of oncogenic forms of  A-, B-, and c-Raf-1 on 
differentiation and MAP kinase activation in PC12 cells 
We [6] and others [24] have previously shown for oncogenic 
forms of c-Raf-1 that they induce differentiation f PC12 cells. 
As our kinetic data on activation of endogenous A- and B- 
Raf suggest hat these are more likely mediators of differen- 
tiation, we examined whether oncogenic versions of A- and 
B-Raf were also able to induce neuronal differentiation of 
PC12 cells. Comparison was made with NGF and another 
retroviral oncogene v-mos, which encodes a serine/threonine 
kinase that has been reported to directly phosphorylate and 
activate MEK in vitro [25,26]. All four constitutively active 
MEK activators induced neurite outgrowth (Fig. 2). However, 
there were subtle differences in morphology of differentiating 
cells. Whereas NGF treated cells formed numerous and very 
branched neurites, the retrovirally introduced kinases induced 
formation of only 2-3 low-branched extensions. After 3 days 
all infected cells had neuronal extensions longer than 3-5 cell 
body diameters, while NGF induced neurits achieved these 
only on day 5 or 6. Fig. 3 shows that only infected cells 
differentiate, since only cells with neurites were stained with 
anti-c-Raf-1 antibodies on day 5 after infection with the con- 
stitutively active form of c-Raf-1. 
As Raf kinases might have multiple substrates and consti- 
tutively active c-Raf-1 was previously thought o be unable to 
induce MAPK activity in PC12 cells, we determined the level 
of MAPK activity in all of the infected cells and compared it
to EGF induction. Fig. 4 shows that MAPK is activated in 
PC12 cells expressing any of the three constitutively activated 
Raf kinases, v-Mos, an alternative MEK activator, was also 
active in this differentiation assay. The lower level of activity 
observed relative to the EGF control may be partly explained 
by the small fraction of exogenous Raf expressing cells (20- 
30%). Kinetic analysis of MAPK activation after retroviral 
infection shows that MAPK activation is only observed after 
36 h (Fig. 4A), the earliest ime at which neurite outgrowth 
was detected (data not shown). 
4. Discussion 
We show here that the differentiation i ducing NGF recep- 
tor differs from the proliferation i ducing EGF receptor in its 
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Fig. 1. Kinetics of c-Raf-1 (A), MEKK (B), B-Raf (C) and A-Raf (D) activation following NGF or EGF stimulation. 5× 107 PC12 cells were 
treated with 50 ng/ml NGF or 50 ng/ml EGF for the times indicated. The appropriate kinases were immunoprecipitated from the cell lysates 
and in vitro kinase assays were performed with the kinase inactive K97M MEK as a substrate as described in section 2. The activity of un- 
treated cells was taken as equal to unity and the relative values are presented. The results presented are the means of three separate xperi- 
ments (error bars represent s andard error of the mean). The relative basal MEK phosphorylating activities of immunoprecipitated emzymes in 
unstimulated cells were 1:5:1:0.6 for A-, B-, c-Raf-1 and MEKK, respectively. The specificity of the immunoassays was tested by competition 
with the corresponding peptides to which the antibodies were raised. In vitro kinase conditions were the same for all three Raf kinases as well 
as MEKK, following established protocol [13,33]. A temporal pattern of MEK phosphorylation f one representative experiment is shown un- 
der each time-course curves. The amounts of immunoprecipitated Raf kinases and MEKK throughout the time course were controlled by im- 
munoblotting analysis. No time-dependent changes in amounts of immunoprecipitated proteins were observed. 
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Fig. 2. Neurite formation in PC12 ceils following infection with retroviruses carrying constitutively active forms of raf and mos DNAs. PC12 
cells were infected with 2x 106 cfu/ml of retroviruses containing cDNA encoding constitutively active mutants of A-Raf (A-Raf 6A), B-Raf 
(BXB B-Raf), c-Raf-1 (EHneo), Mos (v-Mos). Uninfected and NGF stimulated cells were used as controls. On day 6 after treatment the cells 
were fixed and photographed (× 60). 
ability to induce sustained activation of A- and B-Raf iso- 
zymes. We further show that all three constitutively active 
forms of Raf  kinases are able to induce neuronal differentia- 
tion of PC12 cells and to activate MAPK.  Finally, we illus- 
trate by use of a Raf  independent MEK activator, v-mos that 
Raf  is not required for induction of differentiation consistent 
with earlier reports on the activity of oncogenic MEK in PC12 
cells [27,28]. 
Perhaps the most striking finding was the differential re- 
sponse of the three Raf  isozymes to growth factor treatment. 
Clearly, all three enzymes, which overlap in their mode of 
activation in that they all contain a Ras binding domain, 
become rapidly activated upon treatment of cells with either 
EGF  or NGF.  However, after NGF treatment only A- and 
B-Raf showed sustained activation reflecting the sustained 
activation of Ras under these conditions [21], whereas 
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day 1.5 
day 5 
Fig. 3. Overexpression f v-Raf protein induces neurite formation. After 36 h or 5 days of infection with constitutively active c-Raf-1 kinase 
(EHneo) PC12 cells were fixed at -20°C for 5 min with methanol and Raf protein was visualised using the polyclonal rabbit anti-sp-63 antibo- 
dies and the peroxidase ABC staining kit from Vector Laboratories. 
c-Raf-1 which demonstrated the highest degree of initial acti- 
vation was rapidly inactivated. Negative regulation of Raf has 
been observed previously both at the level of activation and 
with active Raf. Phosphorylation f c-Raf-1 on Ser-43 of the 
regulatory domain trough PKA inhibits the Ras dependent 
activation of Raf-1 kinase leading to the downregulation of
the classic cascade and to inhibition of growth factor induced 
cell proliferation of Ratla and NIH 3T3 cells [12,29,30]. In- 
activation of constitutively active c-Raf-1 was observed in 
Jurkat T-cells [31]. Downregulation of the MEK phosphory- 
lating ability of a truncation activated form of Raf-1 called 
BXB, which essentially consists of the kinase domain of c- 
Raf-1 was complete and reversible. As the oncogenic forms 
of all three Raf isozymes were active in the PC12 differentia- 
tion assay, yet only kinase active c-Raf-1 was subject to down- 
regulation, it may be more likely that in these cells negative 
regulation targets the full-length molecule. Alternatively, it
may be that like in Jurkat cells the kinase domain is modified 
so as to render it inactive, but that the capacity of this process 
is limited and becomes overwhelmed by the overexpressed v- 
Raf. In this case we would expect he specific activity of v-Raf 
from PC12 cells to be lower than that in NIH 3T3 cells. 
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Fig. 4. Overexpression of oncogenic forms of Raf and Mos kinases in PC12 cells induce MAPK activation. PC12 cells were infected with retro- 
viruses containing constitutively active form of A-Raf (A-Raf 6A), B-Raf (BXB B-Raf), c-Raf-1 (EHneo) and Mos (v-mos) as described in Fig. 
3. MAPK was immunoprecipitated from cell lysates after different imes of infection with EHneo (A) or after 36 h of infection with the corre- 
sponding retroviruses (B) and phosphorylation f MBP by MAPK immune complexes was analysed. 5 min stimulation of uninfected cells with 
50 ng/ml EGF was used as a positive control. The immunoblot was performed using the ECL detection kit as described in section 2. 
Our demonstration of MAPK activity in BXB Raf-1 ex- 
pressing PC12 cells is in conflict with an earlier report by 
Wood et al. [32] were induction of BXB Raf-1 by dexametha- 
sone from an MTV-LTR based vector led to neurite out- 
growth apparently in the absence of MAPK activation. These 
data are often used to argue for the existence of alternative 
Raf substrates. A more trivial explanation may be the low 
level of MAPK activity in BXB Raf-1 PC12 cells relative to 
that induced by EGF treatment (Fig. 4). Whichever way this 
may be, we consider it unlikely that Raf specific differentia- 
tion substrates come into play, because a Raf independent 
activator of MEK, v-mos like constitutively activated MEK 
[27] is a very potent differentiation i ducer. This is the first 
report of differential regulation of components of the highly 
conserved Ras-Raf-MEK-MAPK signalling cascade by NGF 
and EGF. These findings now raise important questions about 
the underlying mechanisms. Factors important for the reacti- 
vation of c-Raf-1 have to be to identified as well as the basis 
for resistance to downregulation of A- and B-Raf. The rele- 
vant experiments are now in progress. 
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